Financials · MDXG

MiMedx Group Inc (MDXG) financials

For the twelve months ended Sep 30, 2026, MiMedx Group Inc reported $303.73M of revenue and -$19.19M of net income.

Revenue, TTM
$303.73M
Revenue growth, YoY
-22.8%
Net income, TTM
-$19.19M
Net margin
-6.3%
EPS, diluted, TTM
-$0.13
Cash
$120.79M
Total debt
$0
P/S
1.59
Market cap
$482.3M
Annual revenue$418.63M
FY2016FY2025
Annual net income$48.58M
FY2016FY2025
Annual free cash flow$24.79M
FY2021FY2023

MDXG revenue and earnings growth

MDXG revenueQ3 2026$62.28M

Quarter YoY
-45.2%
QoQ
-3.2%
FY YoY
+20.0%
5Y CAGR
+11.0%

MDXG revenue was $62.28M in fiscal Q3 2026 (ended Sep 30, 2026), down 45.2% from a year earlier and down 3.2% from the prior quarter. For the full fiscal 2025 it was $418.63M, up 20.0% from fiscal 2024. Compound annual growth was +11.0% over 5 years. It rose in 6 of the last 9 fiscal years. Fiscal 2025 is the highest of the 11 fiscal years on file.

MDXG net incomeQ3 2026-$8.68M

FY YoY
+14.5%
10Y CAGR
+5.1%

MDXG net income was -$8.68M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $16.75M a year earlier. For the full fiscal 2025 it was $48.58M, up 14.5% from fiscal 2024. Compound annual growth was +5.1% over 10 years.

MDXG EPSQ3 2026-$0.06

FY YoY
+14.3%
10Y CAGR
+2.1%

MDXG diluted EPS was -$0.06 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0.11 a year earlier. For the full fiscal 2025 it was $0.32, up 14.3% from fiscal 2024. Compound annual growth was +2.1% over 10 years.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$418.63M$348.88M$321.48M$267.84M$242.02M$248.23M$299.25M$359.11M$321.14M$221.71M
Cost of revenue$73.01M$60.07M$54.63M$48.32M$39.63M$39.33M$43.08M$36.39M$35.22M$30.94M
Gross profit$345.62M$288.81M$266.84M$219.53M$202.39M$208.90M$256.17M$322.73M$285.92M$190.77M
Research and development$15.10M$12.34M$12.66M$12.70M$9.93M$11.71M$11.14M$15.77M$17.90M$14.34M
Selling, general and admin$266.19M$225.09M$211.12M$208.67M$194.85M$181.02M$198.21M$258.53M$220.12M$173.41M
Operating income$63.89M$58.87M$37.12M-$14.73M-$7.05M-$45.40M-$21.16M-$3.92M$46.22M$884.0K
Interest expense$1.78M$3.94M$6.58M$5.05M-----$339.0K
Pre-tax income$66.26M$57.29M$30.63M-$19.75M-$12.05M-$61.54M-$25.59M-$3.40M$45.09M$545.0K
Income tax$17.68M$15.30M-$36.81M$206.0K$247.0K-$12.26M-$5.0K$26.58M-$19.64M$155.0K
Net income$48.58M$42.42M$58.23M-$30.20M-$10.29M-$49.28M-$25.58M-$29.98M$64.73M$390.0K
EPS, basic$0.33$0.29$0.40-$0.33-$0.15-$0.77-$0.24-$0.28$0.61$0.00
EPS, diluted$0.32$0.28$0.37-$0.33-$0.15-$0.77-$0.24-$0.28$0.56$0.00
Diluted shares149.7M149.0M146.0M112.9M110.4M108.3M106.9M105.6M116.1M112.6M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$166.12M$104.42M$82.00M$65.95M$87.08M$95.81M$69.07M$45.12M$27.48M$30.32M
Short-term investments---------$0
Receivables$75.71M$55.83M$53.87M$43.08M$40.35M$35.42M$32.33M$0-$1.93M
Inventory$25.34M$23.81M$21.02M$13.18M$11.39M$10.36M$9.10M$15.99M$9.47M$15.87M
Current assets$277.47M$191.89M$164.26M$134.20M$148.52M$160.62M$123.25M$74.05M$48.75M$59.47M
Goodwill$19.44M$19.44M$19.44M$19.44M$19.44M$19.98M$19.98M$19.98M$19.98M$20.20M
Total assets$342.65M$263.92M$239.05M$171.43M$187.93M$202.03M$167.17M$122.84M$121.25M$117.27M
Current liabilities$64.27M$45.59M$46.01M$43.56M$42.36M$59.16M$67.32M$71.55M$45.81M$60.79M
Short-term debt$1.50M$1.00M$1.00M--$0$3.75M$0--
Long-term debt$16.47M$17.83M$48.10M$48.59M$48.13M$47.70M$61.91M$0--
Total debt$17.97M$18.83M$49.10M$48.59M$48.13M$47.70M$65.66M$0--
Total liabilities$86.11M$70.81M$96.33M$96.92M$95.35M$110.61M$132.77M$73.19M$47.46M$69.21M
Shareholders' equity$256.55M$193.11M$142.72M-$17.99M$82.0K-$150.0K$34.40M$49.66M$73.80M$48.07M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$74.00M$66.20M$26.77M-$17.89M-$1.98M-$30.26M-$39.41M$35.80M$62.94M$23.85M
Capital expenditures--$1.99M$1.51M$3.22M-----
Free cash flow--$24.79M-$19.41M-$5.20M-----
Investing cash flow-$6.89M-$9.58M-$2.15M-$2.66M-$3.40M-$4.55M$504.0K-$9.22M-$5.40M-$11.68M
Financing cash flow-$5.41M-$34.20M-$8.57M-$580.0K-$3.35M$61.56M$62.86M-$8.93M-$60.39M-$8.15M
Share repurchases$0$0$9.52M$0$0$900.0K-$7.60M$68.30M$10.40M
Stock-based compensation$16.40M$16.93M$16.96M$11.33M$14.16M$15.36M$12.06M$14.77M$21.20M$17.73M
Depreciation and amortization$14.88M$6.04M$3.43M-------

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY20.0%8.5%20.0%10.7%-2.5%-17.0%-16.7%11.8%44.8%-
Net income growth, YoY14.5%-27.2%------16496.7%-98.7%
EPS growth, YoY14.3%-24.3%--------100.0%
Gross margin82.6%82.8%83.0%82.0%83.6%84.2%85.6%89.9%89.0%86.0%
Operating margin15.3%16.9%11.5%-5.5%-2.9%-18.3%-7.1%-1.1%14.4%0.4%
Net margin11.6%12.2%18.1%-11.3%-4.2%-19.9%-8.5%-8.3%20.2%0.2%
Free cash flow margin--7.7%-7.2%-2.1%-----
Return on equity18.9%22.0%40.8%--12542.7%--74.4%-60.4%87.7%0.8%
Return on assets14.2%16.1%24.4%-17.6%-5.5%-24.4%-15.3%-24.4%53.4%0.3%
Current ratio4.324.213.573.083.512.711.831.031.060.98
Debt to equity0.070.100.34-586.91-1.910.00--

Source: XBRL data MiMedx Group Inc files with the SEC, latest filing dated Oct 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

MDXG peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
MDXG$303.73M-22.8%-$19.19M-6.3%$482.3M
SYK$26.30B+7.9%$3.62B13.8%$124.05B
MMM$25.25B+1.7%$3.54B14.0%$95.67B
BSX$21.07B+8.9%$3.50B16.6%$61.96B
BDX$23.25B+17.4%$941.00M4.0%$57.71B
MDLN$30.68B-$683.00M2.2%$52.13B
RMD$5.73B+9.0%$1.59B27.8%$33.10B
DXCM$5.10B+13.0%$991.00M19.4%$29.62B
WST$3.40B+12.6%$638.90M18.8%$27.85B

MDXG FAQ

8 questions
  • What is MDXG revenue?
    MiMedx Group Inc (MDXG) reported $303.73M of revenue for the twelve months ended Sep 30, 2026. That is down 22.8% from the year before. Revenue for fiscal 2025 was $418.63M.
  • Is MDXG profitable?
    No. MiMedx Group Inc reported a net loss of $19.19M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does MDXG have?
    MiMedx Group Inc reported $120.79M in cash and cash equivalents and $0 of debt on its most recent balance sheet in SEC filings.
  • How fast is MDXG revenue growing?
    MiMedx Group Inc's revenue changed +20.0% in fiscal 2025, to $418.63M. Its compound annual growth rate was +11.0% over 5 years.
  • What is MDXG gross margin?
    MiMedx Group Inc's gross profit was $234.75M on $303.73M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 77.3%.
  • What is MDXG earnings per share?
    Diluted earnings per share were -$0.13 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did MDXG last report financial results?
    The latest statements here come from MiMedx Group Inc's 10-Q filed on Oct 28, 2026, covering the period ended Sep 30, 2026.
  • Where does this MDXG financial data come from?
    Quantisnow builds these statements from the structured XBRL data MiMedx Group Inc files with the SEC. It is provided for information only and is not investment advice.